LACTOFERRIN FOR PREVENTION OF COVID-19 IN HEALTH CARE PERSONNEL.

BOVINE LACTOFERRIN FOR THE PREVENTION OF COVID-19 INFECTION IN PHYSICIANS AND NURSES IN HOSPITALS IN LIMA, PERU: A DOUBLE BLINDED RANDOMIZED CLINICAL TRIAL

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

REPEC

Registry ID

PER-064-20

Enrollment

336

Registered

2020-09-29

Start date

2020-10-01

Completion date

Unknown

Last updated

2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Bovine Lactoferrin Type of group

Bovine Lactoferrin 300 mg every twelve hours for 12 weeks. Presentation: 100mg chewable tablets. Group name:Maltodextrin Type of group

Maltodextrin 300 mg every twelve hours for 12 weeks Presentation: 100mg chewable tablets.

Eligibility

Inclusion criteria

Inclusion criteria: 1.- Man or woman over 18 and under 60 years old. 2.- Physicians or nurses who work in areas of care for patients with COVID-19 (emergency, hospitalization, and ICU) in hospitals in Lima, Peru. 3.- Healthy participants, without COVID-19 suggestive symptoms. 4.- Participant who wants to participate and signs the informed consent.

Exclusion criteria

Exclusion criteria: 1.- Participant who had a previous diagnosis of COVID-19. 2.- Participant positive in the initial screening for IgM or IgG positive RT-PCR for COVID-19. 3.- Participant with the following comorbidities: hypertension, coronary heart disease, diabetes mellitus, obesity, chronic lung disease, cancer, kidney failure, or other hematological /and immunosuppressive diseases. 4.- Pregnant woman. 5.- Participant that are part of another clinical trial or is receiving any supplement or preventive treatment for COVID 19. 6.- Participant with known allergy to cow´s milk protein.

Design outcomes

Primary

Measure	Time frame
Outcome name:Serology (IgM or IgG) or RT-PCR for COVID-19 Measure:Number of COVID-19 infections Timepoints:Serology every 4 weeks and RT-PCR if you have symptoms suggestive of COVID-19	—

Secondary

Measure	Time frame
Outcome name:OMS classification Measure:COVID-19 infection severity Timepoints:During the 12 weeks of the study ; Outcome name:Symptom duration data sheet Measure:Duration of the symptomatic phase Timepoints:During the 12 weeks of the study ; Outcome name:Symptom Frequency Data Sheet Measure:Frequency of COVID-19 symptoms Timepoints:During the 12 weeks of the study	—

Countries

Peru

Contacts

Public ContactTheresa Jean Ochoa

UNIVERSIDAD PERUANA CAYETANO HEREDIA

theresa.ochoa@upch.pe996505308

Outcome results